There are more treatments today than ever before to help people with ongoing conditions manage their physical symptoms. But even with these medical advances, a diagnosis of myelodysplastic syndromes ...

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancement Median overall survival (mOS) of 13.4 months in r/r ...

MDS is a rare form of cancer with its own unique characteristics. Here is one patients perspective on the experience of having MDS. “You have myelodysplastic syndrome,” the oncologist told me soberly.

MDS can cause fatigue and reduce your appetite. Here are some nutrient-dense recipes that can boost your energy, support your immune function, and help you better tolerate treatments. Myelodysplastic ...

Dr. Markku Jalkanen, CEO of Faron, remarked on the significance of the EMA's support, emphasizing the company's commitment to developing bexmarilimab as a potentially new and effective therapy for MDS ...